Bio-Rad Labs (BIO) Tops Q2 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $378.24 +0.89%
EPS Growth %: -1.3%
Financial Fact:
Net income including noncontrolling interests: 0
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -1.3%
Financial Fact:
Net income including noncontrolling interests: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $1.64, $0.37 better than the analyst estimate of $1.27. Revenue for the quarter came in at $575.9 million versus the consensus estimate of $548.43 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
